|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Giuliano AE, Connolly JL, Edge SB,
Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ and
Hortobagyi GN: Breast cancer-major changes in the American joint
committee on cancer eighth edition cancer staging manual. CA Cancer
J Clin. 67:290–303. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bertoli G, Cava C and Castiglioni I:
MicroRNAs: New biomarkers for diagnosis, prognosis, therapy
prediction and therapeutic tools for breast cancer. Theranostics.
5:1122–1143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: Metazoan MicroRNAs. Cell.
173:20–51. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang ZJ and Ma SL: miRNAs in breast
cancer tumorigenesis (Review). Oncol Rep. 27:903–910. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Aure MR, Leivonen SK, Fleischer T, Zhu Q,
Overgaard J, Alsner J, Tramm T, Louhimo R, Alnaes GI, Perälä M, et
al: Individual and combined effects of DNA methylation and copy
number alterations on miRNA expression in breast tumors. Genome
Biol. 14:R1262013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ma L, Teruya-Feldstein J and Weinberg RA:
Tumour invasion and metastasis initiated by microRNA-10b in breast
cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Blenkiron C, Goldstein LD, Thorne NP,
Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE,
Green AR, Ellis IO, et al: MicroRNA expression profiling of human
breast cancer identifies new markers of tumor subtype. Genome Biol.
8:R2142007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He K, Li WX, Guan D, Gong M, Ye S, Fang Z,
Huang JF and Lu A: Regulatory network reconstruction of five
essential microRNAs for survival analysis in breast cancer by
integrating miRNA and mRNA expression datasets. Funct Integr
Genomics. 19:645–658. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Betel D, Wilson M, Gabow A, Marks DS and
Sander C: The microRNA.org resource: Targets and expression.
Nucleic Acids Res. 36:D149–D153. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chou CH, Shrestha S, Yang CD, Chang NW,
Lin YL, Liao KW, Huang WC, Sun TH, Tu SJ, Lee WH, et al: miRTarBase
update 2018: A resource for experimentally validated
microRNA-target interactions. Nucleic Acids Res. 46:D296–D302.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tabas-Madrid D, Muniategui A,
Sánchez-Caballero I, Martinez-Herrera DJ, Sorzano CO, Rubio A and
Pascual-Montano A: Improving miRNA-mRNA interaction predictions.
BMC Genomics. 15 (Suppl 10):S22014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Andrés-León E, González Peña D,
Gómez-López G and Pisano DG: miRGate: A curated database of human,
mouse and rat miRNA-mRNA targets. Database (Oxford).
2015:bav0352015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wong N and Wang X: miRDB: An online
resource for microRNA target prediction and functional annotations.
Nucleic Acids Res. 43:D146–D152. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ekimler S and Sahin K: Computational
methods for microRNA target prediction. Genes (Basel). 5:671–683.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Buffa FM, Camps C, Winchester L, Snell CE,
Gee HE, Sheldon H, Taylor M, Harris AL and Ragoussis J:
microRNA-associated progression pathways and potential therapeutic
targets identified by integrated mRNA and microRNA expression
profiling in breast cancer. Cancer Res. 71:5635–5645. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
de Rinaldis E, Gazinska P, Mera A,
Modrusan Z, Fedorowicz GM, Burford B, Gillett C, Marra P,
Grigoriadis A, Dornan D, et al: Integrated genomic analysis of
triple-negative breast cancers reveals novel microRNAs associated
with clinical and molecular phenotypes and sheds light on the
pathways they control. BMC Genomics. 14:6432013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huynh-Thu VA, Irrthum A, Wehenkel L and
Geurts P: Inferring regulatory networks from expression data using
tree-based methods. PLoS One. 5:e127762010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cai WY, Wei TZ, Luo QC, Wu QW, Liu QF,
Yang M, Ye GD, Wu JF, Chen YY, Sun GB, et al: The wnt-β-catenin
pathway represses let-7 microRNA expression through transactivation
of lin28 to augment breast cancer stem cell expansion. J Cell Sci.
126:2877–2889. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Park EY, Chang E, Lee EJ, Lee HW, Kang HG,
Chun KH, Woo YM, Kong HK, Ko JY, Suzuki H, et al: Targeting of
miR34a-NOTCH1 axis reduced breast cancer stemness and
chemoresistance. Cancer Res. 74:7573–7582. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang S, Li Y, Gao J, Zhang T, Li S, Luo A,
Chen H, Ding F, Wang X and Liu Z: MicroRNA-34 suppresses breast
cancer invasion and metastasis by directly targeting Fra-1.
Oncogene. 32:4294–4303. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li X, Liu F, Lin B, Luo H, Liu M, Wu J, Li
C, Li R, Zhang X, Zhou K and Ren D: miR-150 inhibits proliferation
and tumorigenicity via retarding G1/S phase transition in
nasopharyngeal carcinoma. Int J Oncol. 50:1097–1108. 2017.
View Article : Google Scholar
|
|
27
|
Jiang K, Shen M, Chen Y and Xu W: miR-150
promotes the proliferation and migration of nonsmall cell lung
cancer cells by regulating the SIRT2/JMJD2A signaling pathway.
Oncol Rep. 40:943–951. 2018.PubMed/NCBI
|
|
28
|
Xu Y, Luo X, He W, Chen G, Li Y, Li W,
Wang X, Lai Y and Ye Y: Long non-coding RNA PVT1/miR-150/ HIG2 axis
regulates the proliferation, invasion and the balance of iron
metabolism of hepatocellular carcinoma. Cell Physiol Biochem.
49:1403–1419. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tang W, Xu P, Wang H, Niu Z, Zhu D, Lin Q,
Tang L and Ren L: MicroRNA-150 suppresses triple-negative breast
cancer metastasis through targeting HMGA2. Onco Targets Ther.
11:2319–2332. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shu L, Wang Z, Wang Q, Wang Y and Zhang X:
Signature miRNAs in peripheral blood monocytes of patients with
gastric or breast cancers. Open Biol. 8:1800512018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang S, Chen Y, Wu W, Ouyang N, Chen J,
Li H, Liu X, Su F, Lin L and Yao Y: miR-150 promotes human breast
cancer growth and malignant behavior by targeting the pro-apoptotic
purinergic P2X7 receptor. PLoS One. 8:e807072013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu Q, Jin H, Yang Z, Luo G, Lu Y, Li K,
Ren G, Su T, Pan Y, Feng B, et al: MiR-150 promotes gastric cancer
proliferation by negatively regulating the pro-apoptotic gene EGR2.
Biochem Biophys Res Commun. 392:340–345. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ma Z, Shen Y, Zeng Q, Liu J, Yang L, Fu R
and Hu G: MiR-150-5p regulates EGR2 to promote the development of
chronic rhinosinusitis via the DC-Th axis. Int Immunopharmacol.
54:188–197. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Barroga CF, Pham H and Kaushansky K:
Thrombopoietin regulates c-myb expression by modulating micro RNA
150 expression. Exp Hematol. 36:1585–1592. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sun X, Zhang C, Cao Y and Liu E: miR-150
suppresses tumor growth in melanoma through downregulation of MYB.
Oncol Res. 21:317–323. 2019. View Article : Google Scholar
|
|
36
|
Xing L, Xu W, Qu Y, Zhao M, Zhu H, Liu H,
Wang H, Su X and Shao Z: miR-150 regulates B lymphocyte in
autoimmune hemolytic anemia/Evans syndrome by c-Myb. Int J Hematol.
107:666–672. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fu Z and Li D, Jiang W, Wang L, Zhang J,
Xu F, Pang D and Li D: Association of BTLA gene polymorphisms with
the risk of malignant breast cancer in Chinese women of
Heilongjiang province. Breast Cancer Res Treat. 120:195–202. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sekar D, Govene L, Del Rio ML,
Sirait-Fischer E, Fink AF, Brüne B, Rodriguez-Barbosa JI and
Weigert A: Downregulation of BTLA on NKT cells promotes tumor
immune control in a mouse model of mammary carcinoma. Int J Mol
Sci. 19:7522018. View Article : Google Scholar
|
